Eligibility and feasibility of the treatment of chronic hepatitis C in a cohort of Italian HIV-positive patients at a single HIV reference center

AIDS Patient Care and STDs

Volumn 25, Issue 5, 2011, Pages 295-301

  Angeli, E ^a   Mainini, A ^a   Meraviglia, P ^a   Schiavini, M ^a   Ricci, E ^a   Giorgi, R ^a   Gubertini, G ^a   Rizzardini, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955759380     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0342     Document Type: Article

References (39)

1. Rockstroh J, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002. (Pubitemid 41266795)
2. Benhamou Y, Bochet M, di Martino V, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-1058. (Pubitemid 29458296)
3. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C: A European collaborative study. Clin Infect Dis 2004;38:128-133. (Pubitemid 38045883)
4. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2003;36:491-498. (Pubitemid 36241318)
5. The D:A:D Study. Liver-related deaths in persons infected with the human immunodeficiency virus. Arch Intern Med 2006;166:1632-1641.
6. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-431. (Pubitemid 32801070)
7. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus RBV versus PEGIFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 2005;10:309-317. (Pubitemid 41151037)
8. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459. (Pubitemid 38988594)
9. Carrat F, Bani-Sadr FF, Pol S, et al. Pegylated interferon alfa- 2b vs interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004;292:2839-2848. (Pubitemid 39628231)
10. Torriani FJ, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351;438-450. (Pubitemid 38988593)
11. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-F36. (Pubitemid 39179626)
12. Crespo M, Sauleda S, Esteban J, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007;14:228-238. (Pubitemid 46452410)
13. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban clinic. AIDS 2006;20:2631-2639.
14. Nunez M, Ocampo A, Aguirrebengoa K, et al. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008;15:363-369. (Pubitemid 351473628)
15. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (PFR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: A paired liver biopsy study. J Hepatol 2007;46:613-619. (Pubitemid 46402952)
16. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407-413.
17. Fultz SL, Justice AC, Butt AA, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis 2003;36:1039-1046. (Pubitemid 36513290)
18. Mocroft A, Rockstroh J, Soriano V, et al. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis 2006;38:1092-1097. (Pubitemid 44869287)
19. Rauch A, Egger M, Reichen J, Furrer H; Swiss HIV Cohort Study. Chronic hepatitis C in HIV-infected patients: Low eligibility and applicability of therapy with pegylated interferon- a plus ribavirin. J Acquir Immune Def Syndr 2005; 38:238-240. (Pubitemid 40189334)
20. Zinkernagel AS, von Wyl V, Ledergerber B, et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: The Swiss HIV cohort study. Antivir Ther 2006;11:131-142.
21. Nunes D, Saits R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 2006;30:1520-1526. (Pubitemid 44272741)
22. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clin Infect Dis 2003;36:97-100. (Pubitemid 36099103)
23. Butt AA, Khan UA, Shaikh OS et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009;10:25-32.
24. Maida I, Soriano V, Ramos B, Rios P, Gonzalez-Lahoz J, Nunez M. Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference center. HIV Clin Trials 2005;6:329-336. (Pubitemid 43336967)
25. Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: From large trials to real life. J Viral Hepat 2006;13:678-682. (Pubitemid 44401196)
26. Scott JD, Wald A, Kitahata M et al. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDs 2009;23:925-929.
27. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 update recommendations from HIV-HCV International Panel. AIDS 2007;21:1073-1089. (Pubitemid 46763278)
28. Rockstroh J, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-88. (Pubitemid 351228130)
29. Brook G, Main J, Nelson M et al. British HIV association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010;11: 1-30.
30. Cacoub P, Halfon P, Rosenthal E, et al. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009. J Hepatol 2010;53:230-237.
31. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and importance of long-term follow up after acute hepatitis C infection. Hepatology 1999;29:908-914. (Pubitemid 29109609)
32. Alter MJ, Margolis HS, Krawczyriski K et al. The natural history of community acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-1905.
33. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection : host, viral, and environmental factors. JAMA 2000;284:450-456. (Pubitemid 30484478)
34. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003;98: 2281-2288. (Pubitemid 37305371)
35. Crum RM, Galai N, Cohn S, Celentano DD, Vlahov D. Alcohol use and T-lymphocyte subsets among injection drug users with HIV-1 infection: A prospective analysis. Alcohol Clin Exp Res 1996;20:364-371.
36. Swan D, Long J, Carr O, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care STDs 2010;24:753-762.
37. Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathadee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 2005;19: S179-S189. (Pubitemid 41682186)
38. Uberti-Foppa C, de Bona A, Morsica G, et al. Pretreatment of chronic hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33:146-152. (Pubitemid 36793147)
39. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-676. (Pubitemid 47293847)